Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 1891-1897

  Gu, Xin Xing ^a,f   Chen, Jing ^a   Barenkamp, Stephen J ^b   Robbins, John B ^c   Tsai, Chao Ming ^d   Lim, David J ^e   Battey, James ^a  

^a NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e HOUSE EAR INSTITUTE   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPIC ACID; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; BOVINE SERUM ALBUMIN; COMPLEMENT; CORD FACTOR; FREUND ADJUVANT; HYDRAZIDE DERIVATIVE; HYDRAZINE; OLIGOSACCHARIDE; PHOSPHORYL LIPID A; TETANUS TOXOID;

ANIMAL EXPERIMENT; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DETOXIFICATION; DRUG CONJUGATION; DRUG FORMULATION; DRUG SYNTHESIS; FEMALE; IMMUNIZATION; IMMUNODIFFUSION; IMMUNOGENICITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIMULUS LYSATE TEST; LOWER RESPIRATORY TRACT INFECTION; MALE; MORAXELLA CATARRHALIS; MOUSE; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; RABBIT; SINUSITIS; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINE PRODUCTION;

MORAXELLA CATARRHALIS;

EID: 0031954139     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.1891-1897.1998     Document Type: Article

References (61)

1. Ahmed, K., N. Rikitomi, A. Ichinose, and K. Matsumoto. 1991. Possible presence of a capsule in Branhamella catarrhalis. Microbiol. Immuinol. 35: 361-366.
2. Alaeus, A., and G. Stiernstedt. Branhamella catarrhalis scpticemia in an immunocompetent adult. Scand. J. Infect. Dis. 23:115-116.
3. Barenkamp, S. J. 1996. Immunization with high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae modifies experimental otitis media in chinchillas. Infect. Immun. 64:1246-1251.
4. Bhushan, R., R. Craigie, and T. F. Murphy. 1994. Molecular cloning and characterization of outer membrane protein E of Moraxella (Branhamella) catarrhalis. J. Bacteriol. 176:6636-6643.
5. Bluestone, C. D. 1986. Otitis media and sinusitis in children. Role of Branhamella catarrhalis. Drugs 31(Suppl. 3):132-141.
6. Boyle, F. M., P. R. Georghiou, M. H. Tilse, and J. G. McCormack. 1991. Branhamella (Moraxella) catarrhalis: pathogenic significance in respiratory infections. Med. J. Aust. 154:592-596.
7. Campagnari, A. A., K. Shanks, and D. W. Dyer. 1994. Growth of Moraxella catarrhalis with human transferrin and lactoferrin: expression of iron-repressible proteins without siderophore production. Infect. Immun. 62:4909-4914.
8. S. Catlin, B. W. 1990. Branhamella catarrhalis: an organism gaining respect as a pathogen. Clin. Microbiol. Rev. 3:293-320.
9. Chapman, A. J., Jr., D. M. Musher, S. Jonsson, J. E. Clarridge, and R. J. Wallace. 1985. Development of bactericidal antibody during Branhamella catarrhalis infection. J. Infect. Dis. 151:S78-882.
10. Chen, D., J. C. McMichael, K. R. VanDerMeid, D. Hahn, T. Mininni, J. Cowell, and J. Eldridge. 1996. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization. Infect. Immun. 64:1900-1905.
11. Christensen, J. J., N. Q. Hansen, and B. Bruun. 1990. Serum antibody response to outer membrane proteins of Moraxella (Brunhamella) catarrhalis in patients with bronchopulmonary infection. Clin. Diagn. Lab. Immunol. 3:717-721.
12. Cohen, D., S. Ashkenzai, M. S. Green, M. Gdalevich, G. Robin, R. Slepon, M. Yavzori, N. Orr, C. Block, I. Ashkenazi, J. Shemer, D. N. Taylor, T. L. Hale, J. C. Sadoff, D. Pavliakova, R. Schneerson, and J. B. Robbins. 1997. Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349:155-159.
13. Communicable Disease Surveillance Centre. 1992-1995. CDR Weekly Reports. Communicable Disease Surveillance Centre, London. England.
14. Doern, G. V. 1986. Branhamella catarrhalis - an emerging human pathogen. Diagn. Microbiol. Infect. Dis. 4:191-201.
15. Doyle, W. J. 1989. Animal models of otitis media: other pathogens. Pediatr. Infect. Dis. J. 81(Suppl.):S45-S47.
16. Dubois, M., H. Gillis, J. K. Hamilton, A. A. Rebers, and R. Smith. 1956. Colorimetric method for the determination of sugars and related substances. Anal. Biochem. 28:250-256.
17. Edebrink, P., P. E. Jansson, M. M. Rahman, G. Widmalm, T. Holme, M. Rahman, and A. Weintraub. 1994. Structural studies of the O-polysaccharide from the lipopolysaccharide of Moraxella (Branhamella) catarrhalis serotype A (strain ATCC 25238). Carbohydr. Res. 257:269-284.
18. Edebrink, P., P. E. Jansson, M. M. Rahman, G. Widmalm, T. Holme, and M. Rahman. 1995. Structural studies of the O-antigen oligosaccharides from two strains of Moraxella catarrhalis serotype C. Carbohydr. Res. 266:237-261.
19. Edebrink, P., P. E. Jansson, G. Widmalm, T. Holme, and M. Rahman. 1996. The structures of oligosaccharides isolated from the lipopolysaccharide of Moraxella catarrhalis serotype B, strain CCUG 3292. Carbohydr. Res. 295: 127-146.
20. Ejlertsen, T., E. Thisted, F. Ebbesen, B. Olesen, and J. Renneberg. 1994. Branhamella catarrhalis in children and adults. A study of prevalence, time of colonization, and association with upper and lower respiratory tract infections. J. Infect. 29:23-31.
21. Eliasson, I. 1986. Serological identification of Branhamelia catarrhalis. Serological evidence for infection. Drugs 31(Suppl. 3):7-10.
22. Enright, M. C., and H. McKenzie. 1997. Moraxella (Branhamella) catarrhalisclinical and molecular aspects of a rediscovered pathogen. J. Med. Microbiol. 46:360-371.
23. Faden, H., Y. Harabuchi, and J. J. Hong. 1994. Epidemiology of Moraxella catarrhalis in children during the first 2 years of life: relationship to otitis media. J. Infect. Dis. 169:1312-1317.
24. Fomsgaard, J. S., A. Fomsgaard, N. Hoiby, B. Bruun, and C. Galanos. 1991. Comparative immunoehemistry of lipopolysaccharides from Branhamella catarrhalis strains. Infect. Immun. 59:3346-3349.
25. Fung, C. P., M. Powell, A. Seymour, M. Yuan, and J. D. Williams. 1992. The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in 1991. J. Antimicrob. Chemother. 30:47-55.
26. Goldblatt, D., M. V. V. Turner, and R. J. Levinsky. 1990. Branhamella catarrhalis: antigenic determinants and the development of the IgG subclass response in childhood. J. Infect. Dis. 162:1128-1135.
27. 26a.Green, B. A., E. S. Meredith, L. Edwards, and K. F. Jones. 1994. Nontypeable Haemophilus influenzae lipooligosaccharide conjugates as vaccine candidates against NTHi. p. 125-129. In E. Norrby, F. Brown, R. M. Chanock, and H. S. Ginsberg (ed.). Vaccines 94. Cold Spring Harbor Laboratory Press, Plainview, N.Y.
28. 26b.Gu, X.-X., J. Sun, S. Jin, S. J. Barenkamp, D. J. Lim, J. B. Robbins, and J. Battey. 1997. Detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins confers protection against otitis media in chinchillas. Infect. Immun. 65:4488-4493.
29. Gu, X.-X., and C.-M. Tsai. 1993. Preparation, characterization, and immunogenicity of meningococcal lipooligosaccharide-derived oligosaccharide-protein conjugates. Infect. Immun. 61:1873-1880.
30. Gu, X.-X., C.-M. Tsai, M. A. Apicella, and D. J. Lim. 1995. Quantitation and biological properties of released and cell-hound lipooligosaccharides from nontypeable Haemophilus influenza. Infect. Immun. 63:4115-4120.
31. Gu, X.-X., C.-M. Tsai, T. Ueyama, S. J. Barenkamp, J. B. Robbins, and D. J. Lim. 1996. Synthesis, characterization, and immunological properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins. Infect. Immun. 64:4047-4053.
32. Gupta, R. K., S. C. Szu, R. A. Finkelstein, and J. B. Robbins. 1992. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60:3201-3208.
33. Helminen, M. E., I. Maciver, J. L. Latimer, L. D. Cope, G. H. McCracken, and E. J. Hansen. 1993. A major outer membrane protein of Moraxella catarrhalis is a target for antibodies that enhance pulmonary clearance of the pathogen in an animal model. Infect. Immun. 61:2003-2010.
34. Helminen, M. E., I. Maciver, J. L. Latimer, J. Klesney-Tait, L. D. Cope, M. Paris, G. H. McCracken, and E. J. Hansen. 1994. A large, antigenically conserved protein on the surface of Moraxella catarrhalis is a target for protective antibodies. J. Infect. Dis. 170:867-872.
35. Hochstein, H. D., R. J. Elin, J. F. Cooper, E. B. Seligmann, and S. M. Wolff. 1973. Further developments of Limulus amebocyte lysate test. Bull. Parenter. Drug Assoc. 27:139-148.
36. 33a.Jennings, H. J., C. Lugowski, and F. E. Ashton. 1984. Conjugation of meningocoecal lipopolysaccharide R-type oligosaccharides to tetanus toxoid as route to a potential vaccine against group B Neissetia meningitidis. Infect. Immun. 43:407-412.
37. Kemp, A. H., and M. R. A. Morgan. 1986. Studies on the detrimental effects of bivalent binding in a microtiter plate ELISA and possible remedies. J. Immunol. Methods 94:65-72.
38. Marrs, C. F., and S. Weir. 1990. Pili (fimbriae) of Branhamella species. Am. J. Med. 88(Suppl. 5A):36S-40S.
39. Masoud, H., M. B. Perry, J. R. Brisson, D. Uhrin, and J. C. Richards. 1994. Structural elucidation of the backbone oligosaccharide for the lipopolysaccharide of Moraxella cutarrhalis serotype A. Can. J. Chem. 72:1466-1477.
40. 36a.Masoud, H., M. B. Perry, and J. C. Richards. 1994. Characterization of the lipopolysaccharide of Moraxella catarrhalis. Structural analysis of the lipid A from M. catarrhalis serotype A lipopolysaccharide. Eur. J. Biochem. 220:209-216.
41. McLeod, D. T., F. Ahmad, S. Capewell, M. J. Croughan, M. A. Calder, and A. Seaton. 1986. Increase in bronchopulmonary infection due to Branhamella catarrhalis. Br. Med. J. 292:1103-1105.
42. 37a.Murphy, T. F. 1996. Branhamella catarrhalis: epidemiology, surface antigenic structure, and immune response. Microbiol. Rev. 60:267-279.
43. Murphy, T. F., C. Kirkham, and A. J. Lesse. 1993. The major heat-modifiable outer membrane protein CD is highly conserved among strains of Branhamella Catarrhalis. Mol. Microbiol. 10:87-97.
44. Nicotra, B., M. Rivera, J. I. Luman, and R. J. Wallace. 1986. Branhamella catarrhalis as a lower respiratory tract pathogen in patients with chronic lung disease. Arch. Intern. Med. 146:890-893.
45. Rahman, M., T. Holme, I. Jonsson, and A. Krook. 1995. Lack of serotypespecific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection. Eur. J. Clin. Microbiol. Infect. Dis. 14:297-304.
46. Rahman, M., T. Holme, I. Jonsson, and A. Krook. 1997. Human immunoglobulin isotype and IgG subclass response to different antigens of Moraxella catarrhalis. APMIS 105:213-220.
47. 41a.Robhins, J. B., and R. Schneerson. 1990. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:821-832.
48. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
49. Sarubhi, F. A., J. V. V. Myers, J. J. Williams, and C. G. Shell. 1990. Respiratory infections caused by Branhamella catarrhalis. Selected epidemiologic features. Am. J. Med. 88:9S-14S.
50. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson, and D. C. Klenk. 1985. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:76-85.
51. 44a.Svenson, S. B., and A. A. Lindberg. 1981. Artficial Salmonella vaccines: Salmonnella typhimurium O-antigen-specific oligosaccharide-protein conjugates elicit protective antibodies in rabbits and mice. Infect. Immun. 32:490-496.
52. Tanaka, H., K. Oishi, F. Sonoda, A. Iwagaki, T. Nagatake, and K. Matsumoto. 1992. Biochemical analysis of lipopolysacchurides from respiratory pathogenic Branhamella catarrhalis strains and the role of anti-LPS antibodies in Branhamella respiratory infections. J. Jpn. Assoc. Infect. Dis. 66:709-715.
53. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
54. Vaneechoutte, M., G. Verschraegen, G. Claeys, and A. M. Van Den Abeele. 1990. Serological typing of Branhamella catarrhalis strains on the basis of lipopolysaccharide antigens. J. Clin. Microbiol. 28:182-187.
55. Vaneechoutte, M., G. Verschraegen, G. Claeys, B. Weise, and A. M. Van den Abeele. 1990. Respiratory tract carrier rates of Moraxella (Branhamella) catarrhalis in adults and children and interpretation of the isolation of M. catarrhalis from sputum. J. Clin. Microbiol. 28:2674-2680.
56. 48a.Verheul, A. F. M., A. K. Braat, J. M. Leenhouts, P. Hoogerhout, J. T. Poolman, H. Snippe, and J. Verhoef. 1991. Preparation, characterization, and immunogenicity of meningococcal immunotype L2 and L3,7,6, phosphoethanolamide group-containing oligosaccharide-protein conjugates. Infect. Immun. 59:843-851.
57. Wagner, D. K., M. L. Clements, C. B. Reimer, M. Synder, D. L. Nelson, and B. R. Murphy. 1987. Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza Avaccine indicates that nasal wash immunoglobulin G is a transudate from scrum. J. Clin. Microbiol. 25:559-562.
58. Warburg, O., and W. Christian. 1942. Isolation and crystallization of enolase. Biochem. Z. 310:384-421.
59. W.H.O. Expert Committee on Biological Standardization. 1991. Requirements for Haemophilus type b conjugate vaccines. WHO Tech. Rep. Ser. 814:15-37.
60. Yang, Y. P., L. E. Myers, U. McGuinness, P. Chong, Y. Kwok, M. H. Klein, and R. E. Harkness. 1997. The major outer membrane protein, CD, extracted from Moraxella (Branhamella) catarrhalis is a potential vaccine antigen that induces bactericidal antibodies. FEMS Immunol. Med. Microbiol. 17:187-199.
61. Zollinger, W. D., and R. E. Mandrell. 1983. Importance of complement source in bactericidal activity of human antibody and murine monoclonal antibody to meningococcal group B polysaccharide. Infect. Immun. 40:257-264.